I'm LongbridgeAI, I can summarize articles.Circle Pharma secured $92.5 million in Series E funding led by The Column Group, with participation from Nextech Invest, RA Capital, Euclidean Capital, and Eli Lilly. The funds will advance CID-165, an oral macrocyclic cyclin D1 RxL inhibitor, into early clinical development for ER+ breast cancer, expected to begin in Q1 2027.
- Circle Pharma raised USD 92.5 million in an oversubscribed Series E private financing led by The Column Group. * New and existing investors included Nextech Invest, RA Capital, Euclidean Capital, Eli Lilly, among others. * Proceeds will advance CID-165, an oral macrocyclic cyclin D1 RxL inhibitor, into early clinical development for ER+ breast cancer. * CID-165 is expected to enter clinical development in Q1 2027. * Circle Pharma is a clinical-stage biotech developing targeted macrocycle cancer therapies, including a pipeline of cyclin-targeted macrocycles. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Circle Pharma Inc. published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here